PURPOSE: To establish the clinicopathologic and familial differences within Amsterdam I-positive families, showing either tumor microsatellite instability (MSI) or microsatellite stability (MSS) in order to confirm or deny the existence of hereditary nonpolyposis colorectal cancer (HNPCC) without defects in the mismatch repair system. PATIENTS AND METHODS: Sixty-four Amsterdam I-positive families were included in the study for which full, three-generation, family medical histories and colorectal paraffin-embedded tumors were obtained. Both personal and clinicopathologic information of patients were collected. In all cases, both the MSI status and the mismatch repair (MMR) protein expression were analyzed. MMR genetic testing was performed on the MSI families. RESULTS: Of the Amsterdam I-positive families, 59.4% were tumor MSI, and 40.6% were tumor MSS. When comparing both groups, the statistical differences were observed in the age of onset (MSI, 41 years; MSS, 53 years); in the colorectal tumor location, more frequently proximal in MSI cases; in fewer mucinous tumors in MSS; and loss of MMR protein expression in the MSI tumors. Regarding the individual and familial cancer history, we observed a predominance of individuals with multiple primary tumors in MSI pedigrees, as well as differences in the type of tumors developed within the family. CONCLUSION: Our findings support the suspicion of another hereditary colorectal syndrome different from HNPCC and characterized by MSS, the normal MMR immunohistochemical expression, the presence of only colorectal tumors, and the absence of individuals with multiple primary tumors. All these circumstances suggest the existence of a non-MMR gene being responsible for this new syndrome.
PURPOSE: To establish the clinicopathologic and familial differences within Amsterdam I-positive families, showing either tumor microsatellite instability (MSI) or microsatellite stability (MSS) in order to confirm or deny the existence of hereditary nonpolyposis colorectal cancer (HNPCC) without defects in the mismatch repair system. PATIENTS AND METHODS: Sixty-four Amsterdam I-positive families were included in the study for which full, three-generation, family medical histories and colorectal paraffin-embedded tumors were obtained. Both personal and clinicopathologic information of patients were collected. In all cases, both the MSI status and the mismatch repair (MMR) protein expression were analyzed. MMR genetic testing was performed on the MSI families. RESULTS: Of the Amsterdam I-positive families, 59.4% were tumor MSI, and 40.6% were tumor MSS. When comparing both groups, the statistical differences were observed in the age of onset (MSI, 41 years; MSS, 53 years); in the colorectal tumor location, more frequently proximal in MSI cases; in fewer mucinous tumors in MSS; and loss of MMR protein expression in the MSI tumors. Regarding the individual and familial cancer history, we observed a predominance of individuals with multiple primary tumors in MSI pedigrees, as well as differences in the type of tumors developed within the family. CONCLUSION: Our findings support the suspicion of another hereditary colorectal syndrome different from HNPCC and characterized by MSS, the normal MMR immunohistochemical expression, the presence of only colorectal tumors, and the absence of individuals with multiple primary tumors. All these circumstances suggest the existence of a non-MMR gene being responsible for this new syndrome.
Authors: Inês Francisco; Cristina Albuquerque; Pedro Lage; Hélio Belo; Inês Vitoriano; Bruno Filipe; Isabel Claro; Sara Ferreira; Paula Rodrigues; Paula Chaves; Carlos Nobre Leitão; António Dias Pereira Journal: Fam Cancer Date: 2011-12 Impact factor: 2.375
Authors: V V Ravi Kanth; Sandeep Bhalsing; M Sasikala; G V Rao; R Pradeep; Urmila Steffie Avanthi; D Nageshwar Reddy Journal: Tumour Biol Date: 2014-01-10
Authors: Jose Perea; Edurne Alvaro; Yolanda Rodríguez; Cristina Gravalos; Eva Sánchez-Tomé; Barbara Rivera; Francisco Colina; Pablo Carbonell; Rogelio González-Sarmiento; Manuel Hidalgo; Miguel Urioste Journal: World J Gastroenterol Date: 2010-08-07 Impact factor: 5.742
Authors: Michal Kovac; Endre Laczko; Ritva Haider; Josef Jiricny; Hansjakob Mueller; Karl Heinimann; Giancarlo Marra Journal: Fam Cancer Date: 2011-09 Impact factor: 2.375
Authors: Tara E Seery; Argyrios Ziogas; Bruce S Lin; Chuan-Ju G Pan; Michael J Stamos; Jason A Zell Journal: J Gastrointest Surg Date: 2012-12-14 Impact factor: 3.452
Authors: Ashley S Case; Israel Zighelboim; David G Mutch; Sheri A Babb; Amy P Schmidt; Alison J Whelan; Stephen N Thibodeau; Paul J Goodfellow Journal: Gynecol Oncol Date: 2007-11-26 Impact factor: 5.482